Two new biotechnology books due out in March 2008:
Best Practices in Biotechnology Education
22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups
First Edition, March 2008
Perfect Bound, 342 pages, US$74.95
Best Practices in Biotechnology Education is directed at faculty seeking to start or expand biotechnology education programs; policy-makers and economic developers seeking to help meet workforce needs; and, students, scientists, and business professionals looking to enter the industry or upgrade their existing skills.
The cases herein describe a wide variety of programs from high school through Ph.D. programs. Some are in their first years, whereas others are quite mature and have diversified to offer myriad degree and certificate options. There is also strong international representation, with programs from Australia, Canada, New Zealand, South Africa, and the United States.
Best Practices in Biotechnology Business Development
Valuation, Licensing, Cash Flow, Pharmacoeconomics, Market Selection, Communication, and Intellectual Property
First Edition, March 2008
Perfect Bound, 186 pages, US$67.95
Seeking to meet the need to understand how to practice the business of biotechnology, these best practices provide a framework upon which to understand critical issues in biotechnology business development. Experts from a wide range of disciplines have composed best practices based on their experiences and expertise, creating a vital toolbox covering a broad spectrum of topics. These best practices will enable you develop a better understanding of the key elements in these operations and empower you to better manage their implementation
For more information, contact email@example.com.
On returning from a meeting with a small biotechnology firm in which I serve on the advisory board, I was reminded of a novel strategy for attracting venture capital.
One of the challenges is attracting investment is finding an investor aligned with your company’s future directions. Venture capitalists may be interested only in large companies, in small companies, in diagnostic firms, in drug development, etc. One of the challenges, and opportunities, for small firms, is that their future is very uncertain. This makes it difficult to decide how to pitch the company to potential investors, but it also makes it possible to pitch more than one version of the company.
Using a shotgun approach, it is possible to craft several business plans built a common set of resources, each aimed at a different kind of investor, and simultaneously pitch these different plans to appropriate VCs. The reality is that most investors will realize that there is a great deal of flexibility in the business plan, because there are so many unknown elements in a young company, and pitching more investors increases the likelihood of attracting an investment.
After months of work, the January issue of the Journal of Commercial Biotechnology, my first as managing editor, has just been published. The links below will take you to each article:
Volume 14, Issue 1
From the Classroom
Legal and Regulatory Updates
|Legal and regulatory update||PDF|
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in January 2008
*Drugs may be
covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|CARDIOLITE||Bristol Myers Squibb||technetium tc-99m sestamibi kit||4,988,827||JAN 29,2008|
|CHILDREN’S ADVIL||Wyeth Cons||ibuprofen||4,788,220||JAN 08,2008|
|COVERA-HS||Gd Searle Llc||verapamil hydrochloride||5,200,196||JAN 22,2008|
|DEPAKOTE||Abbott||divalproex sodium||4,988,731||JAN 29,2008|
|DEPAKOTE||Abbott||divalproex sodium||5,212,326||JAN 29,2008|
|DEPAKOTE CP||Abbott||divalproex sodium||4,988,731||JAN 29,2008|
|DEPAKOTE CP||Abbott||divalproex sodium||5,212,326||JAN 29,2008|
|DEPAKOTE ER||Abbott||divalproex sodium||4,988,731||JAN 29,2008|
|DEPAKOTE ER||Abbott||divalproex sodium||5,212,326||JAN 29,2008|
|MIRALUMA||Bristol Myers Squibb||technetium tc-99m sestamibi kit||4,988,827||JAN 29,2008|
|TECZEM||Biovail||diltiazem malate; enalapril maleate||4,983,598||JAN 08,2008|
Courtesy of DrugPatentWatch.com